George Avetian, DO
Family Medicine · Upper Darby, PANPI 1851348718
Payments from drug & device makers
Across 166 payments — averaging $110.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Emergent Biosolutions Inc.$11K
- Novo Nordisk$2K
- AstraZeneca$588
- Pfizer$551
- Johnson & Johnson$532
- Merck$525
- plus $3K from 18 others
What the payments were for
- Consulting fees$1,89010%
- Speaking & faculty fees$7,20039%
- Travel & lodging$3,40819%
- Food & beverage$5,73431%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Emergent Biosolutions Inc. | 28 | $10,834 |
| Novo Nordisk | 16 | $2,433 |
| AstraZeneca | 12 | $588 |
| Pfizer | 23 | $551 |
| Johnson & Johnson | 11 | $532 |
| Merck | 16 | $525 |
| Amarin Pharma, Inc. | 12 | $448 |
| Lilly USA, LLC | 14 | $427 |
| Amgen | 6 | $287 |
| AbbVie(2 entities) | 4 | $215 |
| GSK | 7 | $212 |
| Medtronic | 1 | $171 |
| Boehringer Ingelheim | 3 | $145 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Actelion Pharmaceuticals US, Inc. | 1 | $122 |
| Axsome Therapeutics, Inc. | 1 | $122 |
| Daiichi Sankyo Inc. | 1 | $121 |
| Bayer | 1 | $115 |
| Mylan Specialty L.p. | 1 | $101 |
| Alkermes, Inc. | 1 | $96 |
| Genentech USA, Inc. | 2 | $40 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Zyla Life Sciences, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,267 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 160 | $167,171 |
| OzempicSemaglutide | 131 | $154,198 |
| JardianceEmpagliflozin | 88 | $75,183 |
| MounjaroTirzepatide | 35 | $45,983 |
| XareltoRivaroxaban | 46 | $37,328 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $31,657 |
| TradjentaLinagliptin | 27 | $21,106 |
| EntrestoSacubitril/Valsartan | 21 | $17,520 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 41 | $11,511 |
| MyrbetriqMirabegron | 18 | $11,213 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $10,006 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 128 | $9,098 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $8,070 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 42 | $8,021 |
| Atorvastatin Calcium | 487 | $7,667 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $551 | $178,681201 claims |
| Novo NordiskOzempic | $2,433 | $154,198131 claims |
| Boehringer IngelheimJardiance, Tradjenta | $145 | $96,289115 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Shingrix | $212 | $47,74895 claims |
| Lilly USA, LLCMounjaro | $427 | $45,98335 claims |
| Johnson & JohnsonXarelto | $532 | $37,32846 claims |
| AbbVieSynthroid | $215 | $1,61021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Upper Darby
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.